Clinical trials referral resource: Current clinical trials of the anti-VEGF monoclonal antibody bevacizumab.

Given the well-established role of angiogenesis (or new blood vessel formation) in tumor growth and metastasis, antiangiogenic therapy, a concept first proposed by Dr. Judah Folkman,[1] has become increasingly recognized as a promising new anticancer strategy. As the angiogenic switch in tumors reflects the net balance of a diverse group of endogenous angiogenic promoters and inhibitors, a multitude of agents have been developed to target different factors and pathways. Over 20 antiangiogenic drugs are currently undergoing evaluation in phase I, II, and III trials.